Literature DB >> 22421590

Thymic carcinoma: outcomes after surgical resection.

Ikenna C Okereke1, Kenneth A Kesler, Richard K Freeman, Karen M Rieger, Thomas J Birdas, Anthony J Ascioti, Sunil Badve, Robert P Nelson, Patrick J Loehrer.   

Abstract

BACKGROUND: Thymic carcinoma is a rare malignancy with little information regarding outcomes after therapy with curative intent. We undertook a retrospective analysis of all patients who underwent resection of thymic carcinoma at 2 hospitals.
METHODS: From 1990 to 2011, 16 patients (9 men, 7 women) underwent surgical resection of thymic carcinoma at a mean age of 52 years. Patient demographics, extent of surgical resection, and outcomes were compiled.
RESULTS: The distribution of Masaoka stages at presentation was I in 3 (19%), II in 4 (25%), III in 8 (50%), and IV in 1 (6%). Neoadjuvant chemotherapy was administered to 6 patients (38%) whose tumors were deemed to be more locally invasive. Surgical resection included en bloc extrapleural pneumonectomy in 1, lobectomy in 2, and superior vena cava resection and reconstruction in 4. There were no perioperative deaths. Complete resection was achieved in 14 (88%), and of these patients, only 1 experienced local recurrence. At last follow-up, 10 patients were alive and well, 1 patient was alive with disease, and 5 patients had died. Mean survival was 4.2 years.
CONCLUSIONS: Although considered to have greater malignant potential, long-term survival can be achieved in patients with thymic carcinoma who are amenable to surgical therapy. With increased use of computed tomography imaging, patients with early-stage disease are being identified more frequently, and complete surgical resection appears to have favorable cure rates in these patients. Select patients with locally advanced disease can experience long-term survival with a multimodality approach.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22421590     DOI: 10.1016/j.athoracsur.2012.01.014

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  16 in total

1.  Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging.

Authors:  Anya M Litvak; Kaitlin Woo; Sara Hayes; James Huang; Andreas Rimner; Camelia S Sima; Andre L Moreira; Maria Tsukazan; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2014-12       Impact factor: 15.609

2.  Prognostic stratification of thymic epithelial tumors based on both Masaoka-Koga stage and WHO classification systems.

Authors:  Geun Dong Lee; Hyeong Ryul Kim; Se Hoon Choi; Yong-Hee Kim; Dong Kwan Kim; Seung-Il Park
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

3.  Prognostic value of preoperative serum lactate dehydrogenase in thymic carcinoma.

Authors:  Zu-Yang Yuan; Shu-Geng Gao; Ju-Wei Mu; Qi Xue; You-Sheng Mao; Da-Li Wang; Jun Zhao; Yu-Shun Gao; Jin-Feng Huang; Jie He
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 4.  Common and rare carcinomas of the thymus.

Authors:  Anja C Roden; Malgorzata Szolkowska
Journal:  Virchows Arch       Date:  2021-01-03       Impact factor: 4.064

Review 5.  Advances in thymic carcinoma diagnosis and treatment: a review of literature.

Authors:  J Syrios; N Diamantis; E Fergadis; L Katsaros; M Logothetis; Iota Iakovidou; E Lianos; A Grivas; A E Athanasiou
Journal:  Med Oncol       Date:  2014-06-07       Impact factor: 3.064

6.  Thymic carcinoma patients with myasthenia gravis exhibit better prognoses.

Authors:  Wenya Li; Zhifeng Miao; Xudong Liu; Qigang Zhang; Lei Sun; Peiwen Li; Wenke Liu; Lin Zhang
Journal:  Int J Clin Oncol       Date:  2015-07-03       Impact factor: 3.402

7.  Early-stage thymic carcinoma: is adjuvant therapy required?

Authors:  Mitsuaki Sakai; Takuya Onuki; Masaharu Inagaki; Masatoshi Yamaoka; Shinsuke Kitazawa; Keisuke Kobayashi; Kesato Iguchi; Shinji Kikuchi; Yukinobu Goto; Masataka Onizuka; Yukio Sato
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

8.  Multimodality treatment for advanced thymic carcinoma: outcomes of induction therapy followed by surgical resection in 16 cases at a single institution.

Authors:  Yasushi Shintani; Masayoshi Inoue; Tomohiro Kawamura; Soichiro Funaki; Masato Minami; Meinoshin Okumura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-10-14

9.  Treatment and survival analyses of completely resected thymic carcinoma patients.

Authors:  Yanjiao Mao; Shixiu Wu
Journal:  Onco Targets Ther       Date:  2015-09-09       Impact factor: 4.147

Review 10.  Radiotherapy for thymic carcinoma: adjuvant, inductive, and definitive.

Authors:  Ritsuko Komaki; Daniel R Gomez
Journal:  Front Oncol       Date:  2014-01-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.